These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 25193617

  • 1. The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.
    Yarlas A, Yen L, Hodgkins P.
    Qual Life Res; 2015 Mar; 24(3):671-83. PubMed ID: 25193617
    [Abstract] [Full Text] [Related]

  • 2. Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
    Hodgkins P, Yen L, Yarlas A, Karlstadt R, Solomon D, Kane S.
    Inflamm Bowel Dis; 2013 Feb; 19(2):386-96. PubMed ID: 22648999
    [Abstract] [Full Text] [Related]

  • 3. The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
    Solomon D, Yarlas A, Hodgkins P, Karlstadt R, Yen L, Kane S.
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1386-96. PubMed ID: 22536781
    [Abstract] [Full Text] [Related]

  • 4. Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
    Yarlas A, D'Haens G, Willian MK, Teynor M.
    Inflamm Bowel Dis; 2018 Jan 18; 24(2):450-463. PubMed ID: 29361097
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
    Kamm MA, Lichtenstein GR, Sandborn WJ, Schreiber S, Lees K, Barrett K, Joseph R.
    Inflamm Bowel Dis; 2009 Jan 18; 15(1):1-8. PubMed ID: 18671232
    [Abstract] [Full Text] [Related]

  • 7. Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
    D'Haens G, Sandborn WJ, Barrett K, Hodgson I, Streck P.
    Am J Gastroenterol; 2012 Jul 18; 107(7):1064-77. PubMed ID: 22565161
    [Abstract] [Full Text] [Related]

  • 8. The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.
    Yarlas A, Willian MK, Nag A.
    Qual Life Res; 2021 Jul 18; 30(7):1925-1938. PubMed ID: 33651279
    [Abstract] [Full Text] [Related]

  • 9. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
    Sandborn WJ, Travis S, Moro L, Jones R, Gautille T, Bagin R, Huang M, Yeung P, Ballard ED.
    Gastroenterology; 2012 Nov 18; 143(5):1218-1226.e2. PubMed ID: 22892337
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
    Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE.
    Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1094-102. PubMed ID: 18363894
    [Abstract] [Full Text] [Related]

  • 14. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
    Lichtenstein GR, Kamm MA, Boddu P, Gubergrits N, Lyne A, Butler T, Lees K, Joseph RE, Sandborn WJ.
    Clin Gastroenterol Hepatol; 2007 Jan 01; 5(1):95-102. PubMed ID: 17234558
    [Abstract] [Full Text] [Related]

  • 15. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
    Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE.
    Gastroenterology; 2007 Jan 01; 132(1):66-75; quiz 432-3. PubMed ID: 17241860
    [Abstract] [Full Text] [Related]

  • 16. Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
    Sun J, Yuan Y.
    Adv Ther; 2016 Mar 01; 33(3):400-9. PubMed ID: 26898569
    [Abstract] [Full Text] [Related]

  • 17. Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.
    Nikolaus S, Schreiber S, Siegmund B, Bokemeyer B, Bästlein E, Bachmann O, Görlich D, Hofmann U, Schwab M, Kruis W.
    J Crohns Colitis; 2017 Sep 01; 11(9):1052-1062. PubMed ID: 28486634
    [Abstract] [Full Text] [Related]

  • 18. Golimumab in real-world practice in patients with ulcerative colitis: Twelve-month results.
    Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S.
    World J Gastroenterol; 2020 Jun 07; 26(21):2852-2863. PubMed ID: 32550760
    [Abstract] [Full Text] [Related]

  • 19. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
    Hanauer SB, Sandborn WJ, Dallaire C, Archambault A, Yacyshyn B, Yeh C, Smith-Hall N.
    Can J Gastroenterol; 2007 Dec 07; 21(12):827-34. PubMed ID: 18080055
    [Abstract] [Full Text] [Related]

  • 20. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study.
    Van Assche G, Peyrin-Biroulet L, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S.
    Dig Liver Dis; 2016 Jun 07; 48(6):592-600. PubMed ID: 26935454
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.